Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for baxter
44.84
+0.76 (1.72%)
Dec 9 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 44.09 - 44.87
52 week 34.06 - 50.16
Open 44.21
Vol / Avg. 2.49M/4.85M
Mkt cap 24.79B
P/E 5.04
Div/yield 0.13/1.16
EPS 8.89
Shares 543.92M
Beta 0.83
Inst. own 85%
Jan 31, 2017
Q4 2016 Baxter International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 9, 2017
Baxter International Inc at JPMorgan Healthcare Conference - 12:00PM EST - Add to calendar
Nov 29, 2016
Baxter International Inc at Piper Jaffray Healthcare Conference - Webcast
Oct 25, 2016
Q3 2016 Baxter International Inc Earnings Release
Oct 25, 2016
Q3 2016 Baxter International Inc Earnings Call - Webcast
Sep 12, 2016
Baxter International Inc at Morgan Stanley Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 4.96% 3.94%
Operating margin 9.30% 5.58%
EBITD margin - 14.79%
Return on average assets 3.21% 1.68%
Return on average equity 5.93% 4.63%
Employees 50,000 -
CDP Score - 99 B

Address

One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Baxter International Inc., through its subsidiaries, provides a portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics, and pharmacy automation, software and services. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures IV solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, inhalation anesthetics, and biosurgery products. The business also provides products and services related to pharmacy compounding, and drug formulation. The Renal business provides products and services to treat end-stage renal disease, or irreversible kidney failure and acute kidney injuries.

Officers and directors

Jose E. Almeida Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
James K. Saccaro Corporate Vice President and Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
Marcus Schabacker M.D. Ph.D. Chief Scientific Officer, Corporate Vice President
Age: 52
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
.. Karp Corporate Vice President, Controller
Age: 42
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 60
Bio & Compensation  - Reuters
Brik V. Eyre Corporate Vice President, President - Hospital Products
Age: 52
Bio & Compensation  - Reuters
Robert Felicelli Corporate Vice President - Quality
Age: 57
Bio & Compensation  - Reuters
Timothy P. Lawrence Corporate Vice President - Operations
Age: 53
Bio & Compensation  - Reuters
Jill M. Schaaf Corporate Vice President and President - Renal
Age: 52
Bio & Compensation  - Reuters